| Evidence suggesting that discontinuous dosing of ALK kinase inhibitors may prolong control of ALK+ tumors AD Amin, SS Rajan, WS Liang, P Pongtornpipat, MJ Groysman, EO Tapia, ... Cancer research 75 (14), 2916-2927, 2015 | 57 | 2015 |
| Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer? AD Amin, TL Peters, L Li, SS Rajan, R Choudhari, SD Puvvada, ... Molecular Case Studies 3 (3), a001719, 2017 | 36 | 2017 |
| Oncogene overdose: Too much of a bad thing for oncogene-addicted cancer cells AD Amin, SS Rajan, MJ Groysman, P Pongtornpipat, JH Schatz Biomarkers in cancer 7, BIC. S29326, 2015 | 25 | 2015 |
| Fusion transcripts: Unexploited vulnerabilities in cancer? C Neckles, S Sundara Rajan, NJ Caplen Wiley Interdisciplinary Reviews: RNA 11 (1), e1562, 2020 | 24 | 2020 |
| TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors AD Amin, L Li, SS Rajan, V Gokhale, MJ Groysman, P Pongtornpipat, ... Oncotarget 7 (17), 23715, 2016 | 20 | 2016 |
| The mechanism of cancer drug addiction in ALK-positive T-Cell lymphoma SS Rajan, AD Amin, L Li, DC Rolland, H Li, D Kwon, MF Kweh, A Arumov, ... Oncogene 39 (10), 2103-2117, 2020 | 12 | 2020 |
| CRISPR genome editing of murine hematopoietic stem cells to create Npm1-Alk causes ALK+ lymphoma after transplantation SS Rajan, L Li, MF Kweh, K Kunkalla, AD Amin, NK Agarwal, F Vega, ... Blood advances 3 (12), 1788-1794, 2019 | 7 | 2019 |
| Cancer biology functional genomics: From small RNAs to big dreams S Sundara Rajan, KR Ludwig, KL Hall, TL Jones, NJ Caplen Molecular Carcinogenesis 59 (12), 1343-1361, 2020 | 6 | 2020 |
| ETS1, a Target Gene of the EWSR1::FLI1 Fusion Oncoprotein, Regulates the Expression of the Focal Adhesion Protein TENSIN3 VJ Ebegboni, TL Jones, T Brownmiller, PX Zhao, EC Pehrsson, ... Molecular Cancer Research, OF1-OF17, 2024 | 2 | 2024 |
| Enhancing standard of care chemotherapy efficacy using DNA-dependent protein kinase (DNA-PK) inhibition in preclinical models of Ewing sarcoma VJ Collins, KR Ludwig, AE Nelson, S Sundara Rajan, C Yeung, K Vulikh, ... Molecular Cancer Therapeutics, 2024 | 1 | 2024 |
| NPM1-ALK overexpression-driven toxicity in ALCL is partner dependent and mediated by STAT1 antagonism of STAT3 survival signaling, revealing a novel therapeutic strategy SS Rajan, AD Amin, L Li, DCM Rolland, H Li, S Puvvada, Y Lussier, ... Blood 130, 2506, 2017 | 1 | 2017 |
| Over-expression of NPM-ALK drives resistance to TKIs in ALK+ ALCL but is toxic upon drug withdrawal, permitting prolonged tumour control through discontinuous dosing SS Rajan, AD Amin, M Groysman, P Pongtornpipat, J Schatz Cancer research (Chicago, Ill.) 75 (15_Supplement), 5451-5451, 2015 | 1 | 2015 |
| Novel Resistance Mutations to ALK Tyrosine Kinase Inhibition Arising During Cell‐Culture Drug Selections in T‐Cell Lymphoma M Groysman, A Dipak Amin, E Tapia, S Rajan, J Schatz The FASEB Journal 29, 576.1, 2015 | 1 | 2015 |
| Endogenous EWSR1 Exists in Two Visual Modalities That Reflect Its Associations with Nucleic Acids and Concentration at Sites of Active Transcription S Sundara Rajan, VJ Ebegboni, P Pichling, KR Ludwig, TL Jones, ... Molecular and Cellular Biology 44 (3), 103-122, 2024 | | 2024 |
| EWSR1's visual modalities are defined by its association with nucleic acids and RNA polymerase II S Sundara Rajan, VJ Ebegboni, P Pichling, KR Ludwig, TL Jones, ... bioRxiv, 2023.08. 16.553246, 2023 | | 2023 |
| Fusion transcripts: Unexploited vulnerabilities in cancer? CNJ Neckles C, Sundara Rajan S RNAWires, 2019 | | 2019 |
| CRISPR/Cas9 Generation of Npm1-Alk in Transplantable Murine Hematopoietic Stem Cells Accurately Models ALK-Positive Lymphoma in Recipients SS Rajan, L Li, K Kunkalla, AD Amin, N Agarwal, F Vega, JH Schatz Blood 132, 779, 2018 | | 2018 |
| Elucidating the Mechanism of Cancer Drug Addiction in ALK+ ALCL SS Rajan University of Miami, 2018 | | 2018 |
| NPM1‐ALK overexpression‐driven toxicity in ALCL is partner dependent and driven by phosphorylation of novel substrates leading to overstimulation of biosynthetic pathways JH Schatz, S Sundara Rajan, A Amin, L Li Hematological oncology 35, 284-285, 2017 | | 2017 |
| Kinase overexpressing cancers responsive to drug withdrawal AD Amin, SS Rajan, JH Schatz Aging (Albany NY) 7 (10), 752, 2015 | | 2015 |
Yves A. Lussier, B. Engineer., M.D., Fe...Professor and Chair, Department of Biomedical Informatics, University of Utah School of MedicineVerified email at utah.edu
